Citations (35)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Nbaa Masood & Joohi Jimenez-Shahed. (2023) Effective Management of “OFF” Episodes in Parkinson’s Disease: Emerging Treatment Strategies and Unmet Clinical Needs. Neuropsychiatric Disease and Treatment 19, pages 247-266.
Read now
Read now
Pedro Ayuso, Félix Javier Jiménez-Jiménez, Javier Gómez-Tabales, Hortensia Alonso-Navarro, Elena García-Martín & José A. G. Agúndez. (2023) An update on the pharmacogenetic considerations when prescribing dopamine receptor agonists for Parkinson’s disease. Expert Opinion on Drug Metabolism & Toxicology 19:7, pages 447-460.
Read now
Read now
Edoardo Bianchini, Michela Sforza, Domiziana Rinaldi, Marika Alborghetti, Lanfranco De Carolis, Francesco Della Gatta & Francesco E. Pontieri. (2021) Switch from rasagiline to safinamide in fluctuating Parkinson’s disease patients: a retrospective, pilot study. Neurological Research 43:11, pages 950-954.
Read now
Read now
Jens Hagenow, Stefanie Hagenow, Kathrin Grau, Mohammad Khanfar, Lena Hefke, Ewgenij Proschak & Holger Stark. (2020) Reversible Small Molecule Inhibitors of MAO A and MAO B with Anilide Motifs. Drug Design, Development and Therapy 14, pages 371-393.
Read now
Read now
Yuanyuan Zhang, Zewen Li, Hui Tang, Wenjie Ren, Xin Gao, Yangjian Sun, Qiu Xiang Zhao, Fanye Wang & Junhong Liu. (2020) Development and optimization of levodopa and benzylhydrazine orally disintegrating tablets by direct compression and response surface methodology. Drug Development and Industrial Pharmacy 46:1, pages 42-49.
Read now
Read now
Paolo Guglielmi, Simone Carradori, Alessandra Ammazzalorso & Daniela Secci. (2019) Novel approaches to the discovery of selective human monoamine oxidase-B inhibitors: is there room for improvement?. Expert Opinion on Drug Discovery 14:10, pages 995-1035.
Read now
Read now
Danielle S. Shpiner, Sagari Bette, Daniel G. Di Luca & Jason Margolesky. (2019) CVT-301 for the treatment of Parkinson’s disease. Expert Review of Neurotherapeutics 19:7, pages 603-611.
Read now
Read now
Articles from other publishers (28)
Heba M. El-Sayed, Hisham Ezzat Abdellatef, Amr M. Mahmoud, Hassan A.M. Hendawy, Omar M El-Abassy & Hany Ibrahim. (2023) Safinamide detection based on Prussian blue analogue modified Solid-contact potentiometric sensor. Microchemical Journal 191, pages 108829.
Crossref
Crossref
Heba M. El-Sayed, Hisham Ezzat Abdellatef, Hassan A.M. Hendawy, Omar M El-Abassy & Hany Ibrahim. (2023) DoE-enhanced development and validation of eco-friendly RP-HPLC method for analysis of safinamide and its precursor impurity: QbD approach. Microchemical Journal 190, pages 108730.
Crossref
Crossref
Heba M El-Sayed, Omar M El-Abassy, Hisham Ezzat Abdellatef, Hassan A M Hendawy & Hany Ibrahim. (2023) Green Spectrophotometric Platforms for Resolving Overlapped Spectral Signals of Recently Approved Antiparkinsonian Drug (Safinamide) in the Presence of Its Synthetic Precursor (4-Hydroxybenzaldehyde): Applying Ecological Appraisal and Comparative Statistical Studies. Journal of AOAC INTERNATIONAL 106:1, pages 26-33.
Crossref
Crossref
Heba M El-sayed, Ahmed M. Abdel-Raoof, Hisham Ezzat Abdellatef, Hassan A.M. Hendawy, Omar M El-Abassy & Hany Ibrahim. (2022) Versatile eco-friendly electrochemical sensor based on chromium-doped zinc oxide nanoparticles for determination of safinamide aided by green assessment criteria. Microchemical Journal 182, pages 107900.
Crossref
Crossref
Kaiyue Liu, Shiqi Zhou, Jie Zhou, Ruxue Bo, Xiaoyu Wang, Tong Xu, Yuhe Yuan & Bailing Xu. (2022) Discovery of 3, 6-disubstituted isobenzofuran-1(3H)-ones as novel inhibitors of monoamine oxidases. Bioorganic & Medicinal Chemistry Letters 67, pages 128748.
Crossref
Crossref
Eoin Mulroy & Kailash P. Bhatia. 2022. Non-Motor Parkinson's Disease. Non-Motor Parkinson's Disease
241
251
.
Danielle Larson & Tanya Simuni. (2022) New dopaminergic therapies for PD motor complications. Neuropharmacology 204, pages 108869.
Crossref
Crossref
Fabrizio Gardoni. 2022. Glutamate and Neuropsychiatric Disorders. Glutamate and Neuropsychiatric Disorders
313
336
.
Neha Hanna Daniel, Ananya Aravind & Poonam Thakur. (2021) Are ion channels potential therapeutic targets for Parkinson’s disease?. NeuroToxicology 87, pages 243-257.
Crossref
Crossref
Himika Wasan, Devendra Singh, Balu Joshi, Uma Sharma, A. K. Dinda & K. H. Reeta. (2021) Post Stroke Safinamide Treatment Attenuates Neurological Damage by Modulating Autophagy and Apoptosis in Experimental Model of Stroke in Rats. Molecular Neurobiology 58:12, pages 6121-6135.
Crossref
Crossref
Serene Ho & Adrian Wong. (2021) Perioperative management considerations in patients taking prescribed psychoactive medications (including those for depression and Parkinson's disease). Current Opinion in Anaesthesiology 34:5, pages 582-589.
Crossref
Crossref
P. Pérez-Torre, J.L. López-Sendón, V. Mañanes Barral, I. Parees, S. Fanjul-Arbós, E. Monreal, A. Alonso-Canovas & J.C. Martínez Castrillo. (2021) Concomitant treatment with safinamide and antidepressant drugs: Safety data from real clinical practice. Neurología.
Crossref
Crossref
Luminita Crisan, Daniela Istrate, Alina Bora & Liliana Pacureanu. (2020) Virtual screening and drug repurposing experiments to identify potential novel selective MAO-B inhibitors for Parkinson’s disease treatment. Molecular Diversity 25:3, pages 1775-1794.
Crossref
Crossref
Domiziana Rinaldi, Edoardo Bianchini, Michela Sforza, Marika Alborghetti, Silvia Galli, Marco Salvetti, Morena Giovannelli & Francesco E. Pontieri. (2020) The tolerability, safety and efficacy of safinamide in elderly Parkinson’s disease patients: a retrospective study. Aging Clinical and Experimental Research 33:6, pages 1689-1692.
Crossref
Crossref
Violina Kakoty, Sarathlal K C, Sunil Kumar Dubey, Chih Hao Yang, Prashant Kesharwani & Rajeev Taliyan. (2021) The gut-brain connection in the pathogenicity of Parkinson disease: Putative role of autophagy. Neuroscience Letters 753, pages 135865.
Crossref
Crossref
Donald J. AbrahamOla A.M. Ghoneim & Raymond G. Booth. 2003. Burger's Medicinal Chemistry and Drug Discovery. Burger's Medicinal Chemistry and Drug Discovery
1
46
.
Sara Silva, António J. Almeida & Nuno Vale. (2021) Importance of Nanoparticles for the Delivery of Antiparkinsonian Drugs. Pharmaceutics 13:4, pages 508.
Crossref
Crossref
Himika Wasan, Devendra Singh & Reeta KH. (2021) Safinamide in neurological disorders and beyond: Evidence from preclinical and clinical studies. Brain Research Bulletin 168, pages 165-177.
Crossref
Crossref
Jacopo Troisi, Annamaria Landolfi, Pierpaolo Cavallo, Francesca Marciano, Paolo Barone & Marianna Amboni. 2021.
107
149
.
Begum E. Aksoz & Erkan Aksoz. (2020) Vital Role of Monoamine Oxidases and Cholinesterases in Central Nervous System Drug Research: A Sharp Dissection of the Pathophysiology. Combinatorial Chemistry & High Throughput Screening 23:9, pages 877-886.
Crossref
Crossref
Falaq Naz & Yasir Hasan Siddique. (2020) Role of Genes and Treatments for Parkinson’s Disease. The Open Biology Journal 8:1, pages 47-65.
Crossref
Crossref
V.K.D. Krishnaswamy, Phaniendra Alugoju & Latha Periyasamy. (2020) Multifaceted targeting of neurodegeneration with bioactive molecules of saffron (Crocus sativus): An insilco evidence-based hypothesis. Medical Hypotheses 143, pages 109872.
Crossref
Crossref
Michelle Ann C. Sy & Hubert H. Fernandez. (2020) Pharmacological Treatment of Early Motor Manifestations of Parkinson Disease (PD). Neurotherapeutics 17:4, pages 1331-1338.
Crossref
Crossref
Pablo Duarte, Antonio Cuadrado & Rafael León. 2021. Reactive Oxygen Species. Reactive Oxygen Species
229
259
.
Zhipeng Wang, Ge Gao, Chunli Duan & Hui Yang. (2019) Progress of immunotherapy of anti-α-synuclein in Parkinson’s disease. Biomedicine & Pharmacotherapy 115, pages 108843.
Crossref
Crossref
Vikram S. Sawant, Hyeri Park, Soo Yoon Baek, Jieon Lee, Ji Won Choi, Ki Duk Park, Kyung Il Choi, Jihye Seong, Sanghee Lee & Hyunah Choo. (2019) Benzoxazoles as Selective Monoamine Oxidase B (MAO‐B) Inhibitors. Bulletin of the Korean Chemical Society 40:5, pages 457-460.
Crossref
Crossref
Marios G. Krokidis. (2019) Identification of biomarkers associated with Parkinson’s disease by gene expression profiling studies and bioinformatics analysis. AIMS Neuroscience 6:4, pages 333-345.
Crossref
Crossref
Moussa B. H. Youdim. (2018) Monoamine oxidase inhibitors, and iron chelators in depressive illness and neurodegenerative diseases. Journal of Neural Transmission 125:11, pages 1719-1733.
Crossref
Crossref